What Are Xeris Biopharma Holdings Inc.'s Key Financial Figures?
| Fiscal year | FY2025 ended December 31, 2025 | FY2024 ended December 31, 2024 | FY2023 ended December 31, 2023 | FY2022 ended December 31, 2022 |
|---|---|---|---|---|
| Revenue | $292 million | $203 million | $164 million | $110 million |
| Operating income | $25 million | -$34 million | -$44 million | -$82 million |
| Operating margin | 8.5% | -16.6% | -26.8% | -74.3% |
| Net income | $554,000 | -$55 million | -$62 million | -$95 million |
| Net margin | 0.2% | -27.0% | -38.0% | -85.9% |
| Operating cash flow | $29 million | -$37 million | -$47 million | -$103 million |
| Capital expenditures | Not reported | Not reported | Not reported | Not reported |
| Free cash flow | Not reported | Not reported | Not reported | Not reported |
Operating margin widened by 25.1 percentage points between fiscal 2024 and 2025, which separates pricing and cost discipline from revenue growth alone.
What Does Xeris Biopharma Holdings Inc.'s Balance Sheet Show?
| Cash and cash equivalents | $111 million |
|---|---|
| Long-term debt | $220 million |
| Total assets | $384 million |
| Total liabilities | $370 million |
| Shareholders' equity | $14 million |
| Current ratio | 2.2x |
Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions.
Where These Numbers Come From
Every figure on this page is a value Xeris Biopharma Holdings Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001867096-26-000016 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
What was Xeris Biopharma Holdings Inc.'s revenue in fiscal 2025?
Xeris Biopharma Holdings Inc. reported revenue of $292 million for the fiscal year ended December 31, 2025, according to its SEC filings.
What is Xeris Biopharma Holdings Inc.'s operating margin?
Xeris Biopharma Holdings Inc.'s operating margin was 8.5% in fiscal 2025: operating income of $25 million on revenue of $292 million.
How much free cash flow did Xeris Biopharma Holdings Inc. generate?
Xeris Biopharma Holdings Inc. did not report both operating cash flow and capital expenditures under the standard tags for fiscal 2025, so free cash flow is not computed here.